Ocugen, Inc. announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team, aiming to enhance external guidance and strengthen internal expertise. Three renowned retinal surgeons, Jeffrey S. Heier, MD, Peter K Kaiser, MD, and Arshad M. Khanani, MD, MA, FASRS, have joined the Retina SAB. These experts are at the forefront of research and advancements in retinal disease.
The company also made notable leadership appointments to optimize its R&D and clinical efforts. Vijay Tammara, PhD, joined in the newly created position of Chief Development Officer, bringing over 32 years of global regulatory leadership experience. His expertise includes significant contributions to the approval of nine Marketing Authorizations and 12 Orphan Drug Designations.
Abhi Gupta, MBA, was named Executive Vice President, Commercial and Business Development, following the retirement of Mike Shine. Mr. Gupta brings over 20 years of experience in commercial strategy, gene therapy, and corporate development, having led commercialization planning for rAAV gene therapies and played a pivotal role in building Pfizer’s gene therapy portfolio. These appointments are intended to effectively execute Ocugen's corporate strategy as it moves closer to commercialization.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.